HUP0401325A3 - Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds - Google Patents

Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds

Info

Publication number
HUP0401325A3
HUP0401325A3 HU0401325A HUP0401325A HUP0401325A3 HU P0401325 A3 HUP0401325 A3 HU P0401325A3 HU 0401325 A HU0401325 A HU 0401325A HU P0401325 A HUP0401325 A HU P0401325A HU P0401325 A3 HUP0401325 A3 HU P0401325A3
Authority
HU
Hungary
Prior art keywords
isoxazolopyridinones
parkinson
disease
compounds
useful
Prior art date
Application number
HU0401325A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0401325A2 publication Critical patent/HUP0401325A2/hu
Publication of HUP0401325A3 publication Critical patent/HUP0401325A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HU0401325A 2001-08-15 2002-08-14 Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds HUP0401325A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119911.6A GB0119911D0 (en) 2001-08-15 2001-08-15 Organic Compounds
PCT/EP2002/009134 WO2003015780A2 (en) 2001-08-15 2002-08-14 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
HUP0401325A2 HUP0401325A2 (hu) 2004-10-28
HUP0401325A3 true HUP0401325A3 (en) 2005-09-28

Family

ID=9920454

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401325A HUP0401325A3 (en) 2001-08-15 2002-08-14 Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds

Country Status (24)

Country Link
US (1) US7087756B2 (enExample)
EP (1) EP1418912B1 (enExample)
JP (1) JP2005501847A (enExample)
KR (1) KR20040029429A (enExample)
CN (1) CN100384418C (enExample)
AR (1) AR036351A1 (enExample)
AT (1) ATE355059T1 (enExample)
BR (1) BR0211903A (enExample)
CA (1) CA2454762A1 (enExample)
CO (1) CO5560566A2 (enExample)
DE (1) DE60218484T2 (enExample)
EC (1) ECSP044971A (enExample)
ES (1) ES2282467T3 (enExample)
GB (1) GB0119911D0 (enExample)
HU (1) HUP0401325A3 (enExample)
IL (1) IL160018A0 (enExample)
MX (1) MXPA04001419A (enExample)
NO (1) NO20040659D0 (enExample)
PE (1) PE20030356A1 (enExample)
PL (1) PL366848A1 (enExample)
PT (1) PT1418912E (enExample)
RU (1) RU2004107847A (enExample)
WO (1) WO2003015780A2 (enExample)
ZA (1) ZA200400525B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof
US7820705B2 (en) * 2004-05-14 2010-10-26 Irm Llc Compounds and compositions as PPAR modulators
CA2642672A1 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2933609B1 (fr) 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
EP2376079B1 (en) * 2009-01-13 2016-08-10 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
DE102011085038A1 (de) 2011-10-21 2013-04-25 Tesa Se Verfahren zur Kapselung einer elektronischen Anordnung
WO2015048316A1 (en) 2013-09-25 2015-04-02 Van Andel Research Institute Highly potent glucocorticoids
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭
JP7146750B2 (ja) 2016-10-14 2022-10-04 ヴァン アンデル リサーチ インスティテュート 非常に強力な糖質コルチコイドの構造およびデザインのための機構

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7602542L (sv) 1975-03-14 1976-09-15 Sandoz Ag 3-(alfa-iminobensyl)-4-hydroxi-2(lh)-pyridoner
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4049813A (en) * 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
DE2801190A1 (de) * 1977-01-19 1978-07-20 Sandoz Ag 3-(alpha-iminobenzyl)-4-hydroxy-2(1h)- pyridon-derivat
US4238616A (en) * 1977-01-19 1980-12-09 Sandoz, Inc. 3-(Substituted)phenyl-5-(β-hydroxyphenethyl)-N-(alkyl)-isoxazole-4-carboxamides
US4113727A (en) * 1977-04-26 1978-09-12 Sandoz, Inc. Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones
CA2451057A1 (en) * 2001-06-14 2002-12-27 Banyu Pharmaceutical Co., Ltd. Novel isoxazolopyridone derivatives and use thereof

Also Published As

Publication number Publication date
JP2005501847A (ja) 2005-01-20
CO5560566A2 (es) 2005-09-30
DE60218484D1 (de) 2007-04-12
WO2003015780A3 (en) 2003-11-13
HUP0401325A2 (hu) 2004-10-28
WO2003015780A2 (en) 2003-02-27
MXPA04001419A (es) 2004-05-27
PL366848A1 (en) 2005-02-07
ZA200400525B (en) 2005-04-01
CN1635889A (zh) 2005-07-06
ATE355059T1 (de) 2006-03-15
DE60218484T2 (de) 2007-11-15
ES2282467T3 (es) 2007-10-16
US7087756B2 (en) 2006-08-08
ECSP044971A (es) 2004-03-23
GB0119911D0 (en) 2001-10-10
NO20040659L (no) 2004-02-13
RU2004107847A (ru) 2005-05-10
CN100384418C (zh) 2008-04-30
BR0211903A (pt) 2004-09-21
CA2454762A1 (en) 2003-02-27
AR036351A1 (es) 2004-09-01
IL160018A0 (en) 2004-06-20
US20040248893A1 (en) 2004-12-09
PE20030356A1 (es) 2003-05-14
PT1418912E (pt) 2007-05-31
EP1418912A2 (en) 2004-05-19
EP1418912B1 (en) 2007-02-28
NO20040659D0 (no) 2004-02-13
KR20040029429A (ko) 2004-04-06
WO2003015780A8 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
HUP0302956A3 (en) Thioflavin derivatives for use in diagnosis of alzheimer's disease, process for preparation of compounds and pharmaceutical compositions containing them
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
HU0303037D0 (en) Compounds to treat alzheimer's disease and pharmaceutical compositions containing them
HUP0303398A3 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof and pharmaceutical compositions containing the same
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
HUP0402063A3 (en) Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof
PL370554A1 (en) New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
HUP0401086A3 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for preparation of pharmaceutical compositions for the treatment of pain, anxiety or gastrointestinal disorders and process for preparation the compounds
HUP0204431A3 (en) 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use, process for their preparation and pharmaceutical compositions containing them
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0303006A3 (en) Retinoids for the treatment of emphysema, process for their preparation and pharmaceutical compositions containing them
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
AU2002348829A1 (en) Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
HUP0400773A3 (en) 7-(4-tert-butylyclohexyl)-5-ethyl-3h-imidazo[5,1-f][1,2,4]triazin-4-on derivatives, their use pharmaceutical compositions containing them and process for the preparation of the compounds